002737SZSE

Announcement on Obtaining Drug Registration Certificate for Flurbiprofen Gel Patch

Sunflower Pharmaceutical Group Co., Ltd.·June 15, 2026·2 pages

✨ AI Summary

Sunflower Pharmaceutical Group's subsidiary has obtained a drug registration certificate for Flurbiprofen Gel Patch from the NMPA. This non-steroidal anti-inflammatory drug (NSAID) offers topical pain relief with reduced gastrointestinal side effects. The approval allows the company to enter the pain management market, aiming to develop this category into a new growth driver for the "elderly" segment.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Sunflower Pharmaceutical Group Co., Ltd. Announcement on Obtaining Drug Registration Certificate for Flurbiprofen Gel Patch

The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and have no false records, misleading statements, or major omissions.

Sunflower Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company" or "this Company")'s holding subsidiary, Sunflower Pharmaceutical Group (Xiangyang) Longzhong Co., Ltd., recently received the Flurbiprofen Gel Patch Drug Registration Certificate issued by the National Medical Products Administration. The relevant situation is hereby announced as follows:

I. Basic Information of the Drug

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.